In Europe, CAR-T cells against BCMA antigen have been tested in the KarMMa and Cartitude trials in triple-class relapsed/refractory MM, showing promising results also in patients with high-risk cytogenetics (79, 80), that should be confirmed by real world data in larger groups of patients. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.